Formulary Group work programme


The Group meets monthly on the third Tuesday of each month. The following list notes medicines that will be scheduled for review in the next three to four months. This list is indicative and may be subject to change.

Aflibercept (Eylea®) - SMC 1186/16 - Formulary Group decision will be published by 8th March 2017.  (Indication: in adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)).

Alirocumab (Praluent®) - SMC 1147/16 - Formulary Group decision will be published by 8th March 2017. (Indication: as per SMC 1147/16, SmPC update - 4 weekly dose for patients requiring larger LDL-C reduction (>60%)).

Etanercept (Benepali®) - SBAR - Formulary Group decision will be published by 8th March 2017. (Indication: for the treatment of juvenile idiopathic arthritis, paediatric plaque psoriasis, enthesitis-related arthritis and psoriatic arthritis).

Botulinum toxin A (Botox®) - SMC 692/11 - Formulary Group decision will be published by 8th March 2017. (Indication: for the prophylaxis of headaches in adults with chronic migraine whose condition has failed to respond to ≥3 prior oral prophylactic treatments or where medication overuse has been appropriately managed).

Everolimus (Afinitor®) - SMC 1215/15 - Formulary Group decision will be published by 8th March 2017. (Indication: for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease).

Evolocumab (Repatha®) - SMC 1148/16 - Formulary Group decision will be published by 8th March 2017. (Indication: for treatment of adults with heterozygous familial hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet).

Fingolimod (Gilenya®) - SMC 1038/15 - Formulary Group decision will be published by 8th March 2017. (Indication: as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite treatment with at least one disease modifying therapy).

Iron III isomaltoside 1000 (Diafer®) - SMC 1177/16 - Formulary Group decision will be published by 8th March 2017. (Indication: for the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used).

Lonsurf® (trifluridine/tipiracil) - SMC 1221/17 - Formulary Group decision will be published by 8th March 2017. (Indication: for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents).

Nystatin - SBAR - Formulary Group decision will be published by 8th March 2017. (Indication: for the treatment of oral candidiasis, in adults and children over 2 years).

Osimertinib (Tagrisso®) - SMC 1214/17 - Formulary Group decision will be published by 8th March 2017. (Indication: for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC) who have received previous treatment with an EGFR tyrosine kinase inhibitor).

Publication schedule

This web page is updated monthly, within 7 working days of publication of Scottish Medicines Consortium advice.

END